Project Grant P01CA281819
Award Date
9/9/24
Completion Date
8/31/29
Dollars Obligated
$2.4M
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This federal Project Grant award of $599,299 from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the University of Illinois to investigate the role of the enzyme hexokinase 2 (HK2) in liver fibrosis and its connection to non-alcoholic steatohepatitis (NASH)-induced hepatocellular carcinoma (HCC). The research aims to further validate the importance of HK2 in liver fibrosis development and its impact on NASH-induced HCC, a leading cause of...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
The National Cancer Institute (NCI) awarded a 5-year, $646,739 Project Grant (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center to investigate the role of hepatic stellate cells (HSCs) in promoting liver metastasis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The research aims to elucidate the regulatory mechanisms and functional roles of extra-tumoral and intra-tumoral HSCs, as well as the impact of extracellular matrix (ECM)...
This Project Grant award, valued at $593,042.00, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The award will support research by The Leland Stanford Junior University (Stanford University) to investigate the role of the complement pathway in macrophage reprogramming and the progression of hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatohepatitis (MASH). The key research objectives are to:...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is supporting research to develop novel inhibitors of the CYP8B1 protein, which plays a key role in the development of obesity-associated hepatocellular carcinoma (HCC). The $213,284 award to the Beckman Research Institute of the City of Hope will fund two aims: 1) Determining the role of CYP8B1 in obesity-associated HCC using mouse models, and 2) Performing chemical modifications and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $793,324 to the Beckman Research Institute of the City of Hope to discover and validate CYP8B1 inhibitors as potential treatments for hepatocellular carcinoma (HCC). The project aims to: 1) identify CYP8B1 inhibitors through high-throughput screening of a 250,000-compound library; 2) validate hit compounds for potency, specificity, and structure-activity relationships; and 3)...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program provides $571,350.00 in funding to the Sanford Burnham Prebys Medical Discovery Institute (SBP) in La Jolla, California. The award supports research aimed at developing metabolic interventions to halt the progression of pancreatic cancer. SBP, an independent non-profit biomedical research organization, will leverage advanced technologies and...
The National Cancer Institute (NCI) awarded a $2,489,032 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The 5-year award, effective August 1, 2025, will support three highly integrated research projects focused on determining the roles, regulation, and underlying mechanisms of lipid metabolism in ferroptosis, a form of iron-dependent cell death, and exploring novel cancer therapeutic approaches based on these...
This $104,096 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research to identify genetic dependencies specific to subtypes of hepatocellular carcinoma (HCC). The project will utilize a hybrid in vivo and in silico approach to determine whether HCC genetic dependencies demonstrate subtype specificity based on pathomolecular features. Specific aims include: 1) using in vivo loss-of-function screening to assess...